Research programme: selective retinoid X receptor modulators - MaxoCore Pharmaceuticals

Drug Profile

Research programme: selective retinoid X receptor modulators - MaxoCore Pharmaceuticals

Alternative Names: MC-1036; Retinoid X receptor agonists research programme - MaxoCore Pharmaceuticals

Latest Information Update: 30 Nov 2010

Price : $50

At a glance

  • Originator MaxoCore Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Retinoid X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Atherosclerosis; Diabetes mellitus; Hypercholesterolaemia; Insulin resistance; Type 2 diabetes mellitus

Highest Development Phases

  • Preclinical Atherosclerosis; Hypercholesterolaemia; Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 14 Jul 2004 The programme is available for licensing
  • 12 Jul 2004 Preclinical trials in Atherosclerosis in USA (unspecified route)
  • 12 Jul 2004 Preclinical trials in Hypercholesterolaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top